Aequus Pharmaceuticals Inc. (TSXV:AQS.H)
Canada · Delayed Price · Currency is CAD | Market Cap | 663.17K -83.3% |
| Revenue (ttm) | 918.47K +122.3% |
| Net Income | -656.34K |
| EPS | -0.00 |
| Shares Out | 132.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,000 |
| Average Volume | 208,793 |
| Open | 0.0050 |
| Previous Close | 0.0050 |
| Day's Range | 0.0050 - 0.0050 |
| 52-Week Range | 0.0050 - 0.0400 |
| Beta | -0.29 |
| RSI | 46.75 |
| Earnings Date | May 1, 2026 |
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. [Read more]
Financial Performance
In 2024, Aequus Pharmaceuticals's revenue was 584,237, an increase of 129.21% compared to the previous year's 254,896. Losses were -2.18 million, -26.55% less than in 2023.
Financial StatementsNews
Aequus Announces Completion of Previously Announced Sale of ZIMED(R) PF
VANCOUVER, British Columbia – TheNewswire - March 31, 2026 – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“ Aequus ” or the “ Company ”), a specialty pharmaceutical company, today announced that it has c...
Aequus Provides Additional Disclosure in Connection with Annual General and Special Meeting of Shareholders
VANCOUVER, November 13th, 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”) wishes to provide certain additional information in connection with the Company's up...
Aequus Announces Giovanni Di Genova Joining Board of Directors
VANCOUVER, September 22 nd , 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to C...
Aequus Reports Second Quarter 2023 Financial Highlights and General Update
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on de...
Aequus Announces Zimed PF Now Available in Canada
VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF),) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today...
Aequus Announces Zimed PF Website Launch
VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF),) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled t...
Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada
VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF),) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the p...
Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)
VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000...
Aequus Provides General Update and First Quarter 2023 Financial Highlights
VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on dev...
Aequus Provides General Update and Fiscal 2022 Financial Results
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing...
Aequus Grants Stock Options
VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces that it has granted incentive stock option...
Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update
VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today it has entered into a loan agreement...
Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)
VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approve...
Aequus Reports Third Quarter 2022 Financial Highlights
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on de...
Aequus Reports Second Quarter 2022 Financial Highlights and General Update
VANCOUVER, British Columbia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on de...
Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (...
Aequus Resumes Trading on TSX Venture Exchange
VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news release dated July 6, 2022, we will resume trad...
Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products
VANCOUVER, British Columbia, July 06, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive dis...
Aequus Provides General Update and Reports Record 2021 Financial Results
Also reports Financial Results for the 3 months ended March 31, 2022
Aequus Provides Update on Delay in Filing Annual Financial Statements
VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that further to its news release on May 6, 2...
Aequus Announces Delay in Filing Annual Financial Statements
VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that the filing of its audited annual financi...
Aequus Announces Short Term Loan
VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that it has entered into an agreement with Mr...
Aequus Announces Director Resignation
VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and pro...
Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication
Health Canada Submission of Preservative-Free Prescription ‘Zimed PF' Accepted for Screening
Aequus Reports Third Quarter 2021 Financial Highlights
Second Largest Revenue Quarter in Company History and New Evolve Product Sales Double Second Largest Revenue Quarter in Company History and New Evolve Product Sales Double